USPTO serial 87748718
BIO CRYST
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 28, 2018
- Examiner
- MILLER, JUSTIN T
- Law office
- TMO LAW OFFICE 114
What this means
Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use. Continue use in commerce and plan for the 10-year Section 8 and 9 renewal.
Need help with BIO CRYST?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
BioCryst Pharmaceuticals, Inc.
Durham, NC, US
BioCryst Pharmaceuticals, Inc.
Durham, NC, US
BioCryst Pharmaceuticals, Inc.
Durham, NC, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Erica L. Han
Erica L. Han Ropes & Gray LLPPrudential Tower, 800 Boylston StreetBoston, MA 02199-3600United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Pharmaceutical research and drug development; medical and scientific research, namely, conducting clinical trials for others; development of pharmaceuticals for the treatment of infectious, viral, inflammatory, immunological, autoimmune and cardiovascular diseases and disorders; development of pharmaceuticals for the treatment of cancer, namely, cancers of the immune system such as T-cell and B-cell leukemias and lymphomas; development of pharmaceuticals for the treatment of influenza, AIDS, SARS, Ebola, Zika, and West Nile virus; development of pharmaceuticals for the treatment of hereditary angioedema, inflammatory bowel diseases, inflammatory connective tissue diseases and inflammatory skin diseases | ACTIVE | Jan 8, 2018 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by BioCryst Pharmaceuticals, Inc.
- Other trademarks owned by BioCryst Pharmaceuticals, Inc.
- Other trademarks owned by BioCryst Pharmaceuticals, Inc.
- Other trademarks in Class 042
- Similar marks named BIO CRYST
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 3, 2025 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Dec 2, 2025 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Dec 19, 2024 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Dec 19, 2024 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Dec 19, 2024 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jul 18, 2024 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Aug 28, 2023 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| May 3, 2023 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Jul 21, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 21, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 21, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 6, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 6, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 6, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 16, 2021 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 16, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 16, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 16, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 16, 2021 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Aug 28, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 12, 2018 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 12, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 12, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 23, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 3, 2018 | ALIE | ASSIGNED TO LIE | — |
| Apr 26, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 16, 2018 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 16, 2018 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Apr 16, 2018 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Apr 16, 2018 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 13, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 24, 2018 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Jan 23, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 12, 2018 | NWAP | NEW APPLICATION ENTERED | — |